Rafferty Asset Management
ONC icon

Rafferty Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Rafferty Asset Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,487
Closed -$327K – 1172
2022
Q4 		$327K Buy
+1,487
New +$273K ﹤0.01% 999
2022
Q3 		– Sell
-1,647
Closed -$267K – 1266
2022
Q2 		$267K Buy
1,647
+215
+15% +$33.6K ﹤0.01% 952
2022
Q1 		$270K Buy
+1,432
New +$304K ﹤0.01% 1117

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rafferty Asset Management's ONC Position: Q1 2023 in Review

Rafferty Asset Management sold out of BeOne Medicines Ltd (ONC) in Q1 2023, closing a stake of 1,487 shares — an estimated $327K sold.

Rafferty Asset Management first reported a position in ONC in Q1 2022 and held it in 3 quarters. The position peaked at $327K in Q4 2022. 220 funds tracked by Wall St. Rank hold ONC as of Q1 2023.

  • Rafferty Asset Management reported no remaining BeOne Medicines Ltd position as of Q1 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 1,487 BeOne Medicines Ltd shares in Q1 2023, an estimated $327K.
  • Rafferty Asset Management first reported a position in BeOne Medicines Ltd in Q1 2022 and held it in 3 quarters.
  • Rafferty Asset Management's BeOne Medicines Ltd position peaked at $327K in Q4 2022.
  • 220 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2023.

Based on Rafferty Asset Management's 13F filing for Q1 2023, filed 11 May 2023.